Ocugen’s $115 Million Convertible Note Clears the Decks for a Three-Drug Regulatory Sprint

Ocugen secures $99.5M net from convertible notes to retire high-interest debt, funding three gene therapy programs toward 2028 FDA submissions despite recent stock dip.

The gene therapy developer is swapping expensive debt for cheaper financing, giving itself a cash runway into 2028 while investors digest a steep near-term share price decline.

Ocugen has completed a private placement of convertible notes worth $115 million, with net proceeds of roughly $99.5 million flowing into the company’s coffers. The deal, which matures in 2034, allows investors to convert their holdings into equity at an initial price of approximately $2.68 per share — a hefty premium to the current trading level. That conversion option becomes exercisable no earlier than May 2027.

A chunk of the fresh capital is earmarked for retiring existing high-interest debt, a move that eliminates double-digit borrowing costs from the balance sheet. Once the transaction closes, Ocugen expects to hold around $112 million in cash, giving management the financial breathing room to push three gene therapy programs toward regulatory approval without the spectre of an imminent cash crunch.

Pipeline Timelines Tighten

The company is targeting three New Drug Applications by 2028, with the first submission slated for the third quarter of 2026. Lead candidate OCU400, a treatment for retinitis pigmentosa, has already completed patient enrolment in its Phase 3 study. Ocugen plans to initiate a rolling Biologics License Application review with the FDA in Q3 2026, with a potential approval decision expected by the end of 2027. Pivotal data from that trial are due in early 2027.

A second programme, OCU410ST for Stargardt disease, is also gathering momentum. Patient recruitment for its registrational study finished ahead of schedule, and investors are eyeing interim results in late summer or early autumn. A third candidate, targeting geographic atrophy, recently posted a 31% reduction in lesion growth in a Phase 2 trial.

Rising Costs, Falling Share Price

The accelerated development comes at a price. Operating expenses climbed to $19.4 million in the first quarter, contributing to a net loss of $0.06 per share — a slight miss against analyst expectations. The stock has shed roughly 16% over the past month, trading at around €1.23 to €1.24, and has slipped below its 200-day moving average.

Despite the near-term jitters, the longer-term picture tells a different story. Ocugen shares have rallied 112% over the past twelve months, reflecting optimism that the pipeline can deliver. The convertible note removes the immediate financing overhang, but the next catalyst is clinical, not financial. With interim data for OCU410ST due in the coming months and the OCU400 rolling review set to begin next year, the company’s valuation will increasingly hinge on trial readouts rather than balance-sheet manoeuvres.